Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369620 | 0.94 | HRH3 (0.47) | ACACBHRH3NOTUMPNMTDPP7 | |
| SCHEMBL13939996 | 0.89 | DPP7 (0.51) | ACACBNOTUMPNMTDPP7DRD2 | |
| SCHEMBL23328576 | 0.86 | HRH3 (0.48) | ACACBHRH3PNMTDRD2DRD3 | |
| SCHEMBL29964619 | 0.84 | ACACB (0.49) | ACACBNOTUMDPP7PHGDHDRD2 | |
| SCHEMBL3398601 | 0.81 | ACACB (0.47) | ACACBNOTUMDPP7PHGDHDRD2 | |
| SCHEMBL27749066 | 0.81 | ACACB (0.49) | ACACBNOTUMDPP7PHGDHDRD2 | |
| SCHEMBL4390014 | 0.80 | ACACB (0.51) | ACACBHRH3PNMTPHGDHDRD2 | |
| SCHEMBL13133948 | 0.79 | HTR5A (0.50) | HRH3PNMTDRD2DRD3DRD1 | |
| SCHEMBL12968836 | 0.79 | MAOA (0.53) | ACACBNOTUMPHGDHDRD2DRD3 | |
| SCHEMBL6370128 | 0.79 | DRD2 (0.50) | HRH3PNMTDRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309612-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | OCUTERRA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309612-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | KCNQ2, KCNQ1, KCNQ3 | ACACB 3345/4885HRH3 1100/4885NOTUM 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.